Elisabetta Moscarella

Prof. Elisabetta Moscarella

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EMEmanuele Monda
Emanuele Monda
GPGiuseppe Palmiero
Giuseppe Palmiero
MRMarta Rubino
Marta Rubino
FVFederica Verrillo
Federica Verrillo
FAFederica Amodio
Federica Amodio
Giuseppe LimongelliGiuseppe Limongelli
Giuseppe Limongelli
Cardiomyopathies (CMPs) represent a diverse group of heart muscle diseases, grouped into specific morphological and functional phenotypes. CMPs are associated with mutations in sarcomeric and non-sarcomeric genes, with several suspected epigenetic and environmental mechanisms involved in determining penetrance and expressivity. The understanding of the underlying molecular mechanisms of myocardial diseases is fundamental to achieving a proper management and treatment of these disorders. Among these, inflammation seems to play an important role in the pathogenesis of CMPs. The aim of the present study is to review the current knowledge on the role of inflammation and the immune system activation in the pathogenesis of CMPs and to identify potential molecular targets for a tailored anti-inflammatory treatment.

1 April 2016 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
PDF file
EMElisabetta Moscarella
Elisabetta Moscarella
AIAlfonso Ielasi
Alfonso Ielasi
FGFrancesco Granata
Francesco Granata
SCSebastian Coscarelli
Sebastian Coscarelli
ESEugenio Stabile
Eugenio Stabile
AVAttilio Varricchio
Attilio Varricchio
Background—: Treatment of in-stent restenosis (ISR) is still challenging. In this setting, the use of bioresorbable vascular scaffold (BVS) seems attractive because it allows drug delivery combined with transient vessel scaffolding. We aimed to investigate the long-term results after BVS use in ISR lesions. Methods and Results—: A prospective analysis was performed on all patients who underwent percutaneous coronary intervention with BVS implantation for ISR at 7 Italian Centers. Primary end point was the device-oriented composite end point (cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization) at the longest follow-up available. From April 2012 to June 2014, 116 patients (127 lesions) underwent percutaneous coronary intervention for ISR with BVS implantation. Among the ISR lesions, the majority were drug-eluting stent ISR (78, 61.6%), de novo ISR (92, 72.4%), and diffuse ISR (81, 63.8%). Procedural success was achieved for all (100%) patients. No in-hospital death, myocardial infarction, or revascularization occurred. At 15 months of follow-up, the incidence of the device-oriented composite end point estimated with the Kaplan–Meier method was 9.1%. No significant differences were reported between drug-eluting stent and bare-metal stent ISR groups in terms of device-oriented composite end point (10.9% versus 6.4%; hazard ratio, 1.7; 95% confidence interval, 0.5–6.5; P =0.425) and its singular components (cardiac death: 2.8% versus 2.0%, hazard ratio, 1.3; 95% confidence interval, 0.1–14.1, P =0.843; target vessel myocardial infarction: 1.5% versus 0%, P =0.421; ischemia-driven target lesion revascularization: 9.6% versus 4.4%, hazard ratio, 2.3; 95% confidence interval, 0.5–10.8, P =0.309). Conclusions—: Our registry suggests that the use of BVS implantation for the treatment of complex drug-eluting stent and bare-metal stent ISR lesions might be associated with acceptable long-term clinical outcomes.

1 October 2020 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
Paolo CalabròPaolo Calabrò
Paolo Calabrò
Felice GragnanoFelice Gragnano
Felice Gragnano
ACArturo Cesaro
Arturo Cesaro
FMFabio Marsico
Fabio Marsico
IPIvana Pariggiano
Ivana Pariggiano
Raffaele De CaterinaRaffaele De Caterina
Raffaele De Caterina

23 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Felice GragnanoFelice Gragnano
Felice Gragnano
ACAntonio Capolongo
Antonio Capolongo
FTFabrizia Terracciano
Fabrizia Terracciano
Giuseppe GargiuloGiuseppe Gargiulo
Giuseppe Gargiulo
VSVincenzo De Sio
Vincenzo De Sio
Paolo CalabròPaolo Calabrò
Paolo Calabrò
Dual antiplatelet therapy (DAPT) is the gold standard for the antithrombotic management of patients with an acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI). Implementation of intensified or prolonged DAPT regimens has proven to lower the risk of ischemic events but at the expense of increased bleeding. Importantly, bleeding is a predictor of poor prognosis. Risk stratification and selection of tailored antiplatelet strategies to maximize the net clinical benefit in individual patients with ACS or undergoing PCI is therefore potentially beneficial. Recently, novel approaches including DAPT de-escalation or escalation have been proposed as possible alternatives to standard DAPT. These strategies, which are generally based on patient’s risk profile, genetics, and/or platelet function have been proposed to offer more tailored treatments in patients with ACS or PCI, with the ultimate goal of providing adequate ischemic protection while mitigating the risk of bleeding. This review summarizes the available evidence on DAPT de-escalation or escalation (both guided and unguided) and discusses the practical implications of these strategies in the contemporary management of patients with ACS and/or undergoing PCI.

1 August 2017 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
EMElisabetta Moscarella
Elisabetta Moscarella
AIAlfonso Ielasi
Alfonso Ielasi
MAMaria Carmen De Angelis
Maria Carmen De Angelis
FUFortunato Scotto di Uccio
Fortunato Scotto di Uccio
ECEnrico Cerrato
Enrico Cerrato
AVAttilio Varricchio
Attilio Varricchio
Bioresorbable vascular scaffolds (BRS) represent the latest innovation in the field of interventional cardiology. BRS have recently been introduced in routine clinical practice and their use has progressively extended in everyday clinical practice. The BRS use appears theoretically attractive in patients presenting with acute coronary syndromes (ACS) as they are generally young with long life expectancy, thus possibly benefiting more of the so-called vascular reparative therapy. Furthermore, “culprit” lesions are usually softer and more easily expandable by current BRS compared to stable chronic lesions. However an increased risk of BRS thrombosis has been reported in clinical trials excluding ACS patients. Therefore, concerns have been raised on the safety of BRS implantation in the ACS setting in which the risk of thrombotic recurrences is definitely higher (compared to stable lesions) independently by the device implanted. Aim of this review is to provide an overview of the available data on the BRS performance in ACS patients.

24 April 2020 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
PDF file
MCMario Crisci
Mario Crisci
Felice GragnanoFelice Gragnano
Felice Gragnano
Marco Di MaioMarco Di Maio
Marco Di Maio
VDVincenzo Diana
Vincenzo Diana
EMElisabetta Moscarella
Elisabetta Moscarella
Paolo CalabròPaolo Calabrò
Paolo Calabrò
Background: Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor is recommended for at least 12 months in patients after an acute coronary syndrome (ACS). However, its underuse and premature discontinuation are common in clinical practice. We aimed to investigate the impact of a dedicated follow-up strategy with clinical visits and counselling on adherence levels to ticagrelor in patients after ACS. Methods: PROGRESS (PROmotinG dual antiplatelet therapy adheREnce in the setting of acute coronary Syndromes) is a prospective, randomized trial enrolling 400 ACS patients treated with ticagrelor. Patients were randomized to be followed-up in a dedicated outpatient clinic (In-person follow-up group, [IN-FU], n=200), or with scheduled for phone interviews only (Telephone follow-up group [TEL-FU], n=200), to assess ticagrelor adherence and related complications. DAPT disruption was defined as an interruption of the administration of the drug due to complications or other reasons of non-adherence, and divided according to the duration into short (1-5 days), temporary (6-30 days) and permanent (≥30 days) disruption. The primary endpoint was the rate of DAPT disruption at 1-year follow-up. Results: The rate of ticagrelor disruption at 1 year follow-up was higher in the TEL-FU group than in the IN-FU group (19.6 vs 5.5%; p<0.0001). The IN-FU group reported a significantly lower rate of short (3.0 vs 8.5%; p=0.012) and permanent (2.0 vs 9.6%; p=0.012) disruption than TEL-FU group. The rate of major bleeding did not differ significantly between the 2 groups (p=0.450). Conclusion: The PROGRESS trial showed a net reduction in DAPT disruption in patients followed-up with clinical (in-person) follow-up visits in a dedicated outpatient clinic compared with those scheduled for phone interviews only.